Roche Holding (RHHBY)
(Delayed Data from OTC)
$29.75 USD
-0.07 (-0.23%)
Updated May 1, 2024 04:00 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RHHBY 29.75 -0.07(-0.23%)
Will RHHBY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RHHBY
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Other News for RHHBY
Genmab: A Complicated Tale
FTC expands patent listing challenges for drugs
J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade
Roche: Value Remains Despite Covid-19 Revenue Growth Loss
AbbVie's Q1: Positive Surprise